Previous 10 | Next 10 |
2023-05-03 22:53:07 ET Glaukos Corporation (GKOS) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns – Chairman and Chief Executive Officer Joe...
2023-05-03 16:37:57 ET Glaukos press release ( NYSE: GKOS ): Q1 Non-GAAP EPS of -$0.59 misses by $0.01 . Revenue of $73.9M (+9.2% Y/Y) beats by $6.16M . 2023 Revenue Guidance The company expects 2023 net sales to be in the range of $295 million to $300 mill...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: ...
2023-05-02 17:35:56 ET Glaukos ( NYSE: GKOS ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, after market close. The consensus EPS Estimate is -$0.58 (-52.6% Y/Y) and the consensus Revenue Estimate is $67.74M (+0.1% Y/Y). Over the last 2 years, GKO...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2022 Sustainability Report. The report highlights the company...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 fina...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration...
Glaukos Corporation (GKOS) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns – Chief Executive Officer Alex Thurman – Chief Financial O...
Glaukos press release ( NYSE: GKOS ): Q4 Non-GAAP EPS of -$0.53 beats by $0.02 . Revenue of $71.22M (-2.7% Y/Y) beats by $3.15M . Glaucoma net sales of $52.9 million and Corneal Health net sales of $18.3 million in Q4 2022. Introduced 2023 net sales guidance range ...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...